Report Detail

Pharmaceuticals & Healthcare Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals

  • RnM3811672
  • |
  • 10 October, 2019
  • |
  • Global
  • |
  • 108 Pages
  • |
  • GlobalData
  • |
  • Pharmaceuticals & Healthcare

1. Table of Contents

    1. Table of Contents 2

    • 1.1. List of Tables 5
    • 1.2. List of Figures 7

    2. Deals in Pharmaceutical & Healthcare Industry Decreased in Q4 2019 9

    • 2.1. Pharmaceuticals & Healthcare, Deal Summary, Q4 2019 9

    3. Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2019 13

    • 3.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2019 13
    • 3.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2019 15
    • 3.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2019 16
    • 3.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2019 17
      • 3.4.1. AbbVie Raises USD30 Billion in Private Placement of Notes 17
      • 3.4.2. Novartis Acquires Medicines Co 17
      • 3.4.3. Stryker to Acquire Wright Medical 18
      • 3.4.4. Mitsubishi Chemical to Acquire Remaining 46.31% Stake in Mitsubishi Tanabe Pharma for USD4.52 Billion 19
      • 3.4.5. Roche to Enter into Licensing Agreement with Sarepta Therapeutics 19

    4. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 20

    • 4.1. Pharmaceuticals & Healthcare, Global, M&A, Q4 2019 20
      • 4.1.1. Top M&A Deals in Q4 2019 21
      • 4.1.3. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2018 - Q4 2019 22
    • 4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2019 23
      • 4.2.1. Top Initial Public Offerings in Q4 2019 24
      • 4.2.2. Top Secondary Offerings in Q4 2019 24
      • 4.2.3. Top PIPE Deals in Q4 2019 25
      • 4.2.4. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2018 - Q4 2019 26
    • 4.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2019 27
      • 4.3.1. Top Venture Financing Deals in Q4 2019 28
      • 4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2019 29
      • 4.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2019 31
      • 4.3.6. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2018 - Q4 2019 32
      • 4.3.7. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2018 - Q4 2019 33
      • 4.3.8. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2018 - Q4 2019 34
    • 4.5. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2019 35
      • 4.5.1. Top Private Equity Deals in Q4 2019 36
      • 4.5.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2018 - Q4 2019 37

    5. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2019 38

    • 5.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2019 38
    • 5.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2018 - Q4 2019 39
    • 5.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2019 41
      • 5.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2019 42
      • 5.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2019 42
      • 5.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2019 43
    • 5.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 - Q4 2019 44
    • 5.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2018 - Q4 2019 46
    • 5.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2018 - Q4 2019 47
    • 5.8. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 - Q4 2019 48

    6. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2019 50

    • 6.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2019 50
    • 6.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 - Q4 2019 51
      • 6.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2019 52
      • 6.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2019 52
      • 6.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2019 53
    • 6.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2018 - Q4 2019 54
    • 6.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2018 - Q4 2019 55
    • 6.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2018 - Q4 2019 57
    • 6.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2018 - Q4 2019 58
    • 6.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2018 - Q4 2019 60

    7. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 62

    • 7.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2019 62
      • 7.1.1. Oncology - Deals of the Quarter 63
    • 7.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2019 65
      • 7.2.1. Central Nervous System - Deals of the Quarter 66
    • 7.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2019 69
      • 7.3.1. Infectious Disease - Deals of the Quarter 70
    • 7.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2019 71
      • 7.4.1. Immunology - Deals of the Quarter 72
    • 7.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2019 74
      • 7.5.1. Metabolic Disorders - Deals of the Quarter 75
    • 7.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2019 77
      • 7.6.1. Cardiovascular - Deals of the Quarter 78
    • 7.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2019 80
      • 7.7.1. Gastrointestinal - Deals of the Quarter 81
    • 7.8. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2019 83
      • 7.8.1. Dermatology - Deals of the Quarter 84
    • 7.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2019 86
      • 7.9.1. Respiratory - Deals of the Quarter 87
    • 7.10. Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2019 89
      • 7.10.1. Ophthalmology - Deals of the Quarter 90

    8. Deal Summary by Geography 92

    • 8.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2019 92
      • 8.1.1. North America - Deals of the Quarter 93
    • 8.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2019 96
      • 8.2.1. Europe - Deals of the Quarter 97
    • 8.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2019 100
      • 8.3.1. Asia-Pacific - Deals of the Quarter 101
    • 8.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2019 102
      • 8.4.1. Rest of the World - Deals of the Quarter 103

    9. Pharmaceuticals & Healthcare, Global, Top Advisors 104

    • 9.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2018 - Q4 2019 104
    • 9.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2018 - Q4 2019 106

    10. Further Information 108

    • 10.1. Methodology 108
    • 10.2. About GlobalData 108
    • 10.3. Contact Us 109
    • 10.4. Disclosure information 109

    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2019

    Summary

    GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2019” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

    Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

    Scope

    - Analysis of the market trends for the pharmaceutical industry in the global arena.
    - Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
    - Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
    - Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
    - Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
    - Analysis of partnership and licensing deals based on clinical stage of development of products.
    - Summary of the pharmaceutical deals globally in the five quarters.
    - Information on the top deals happened in the pharmaceutical industry.
    - Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
    - League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

    Reasons to buy

    - Enhance your decision making capability in a more rapid and time sensitive manner.
    - Find out the major deal performing segments for investments in your industry.
    - Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
    - Identify companies that are aggressively looking to raise capital in the market
    - Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
    - Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
    - Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
    - Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
    - Identify growth segments and opportunities in each region within the industry.
    - Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


    Summary:
    Get latest Market Research Reports on Partnerships, Licensing, Investments and M&A Deals. Industry analysis & Market Report on Partnerships, Licensing, Investments and M&A Deals is a syndicated market report, published as Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals. It is complete Research Study and Industry Analysis of Partnerships, Licensing, Investments and M&A Deals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $1,500.00
    $3,000.00
    $4,500.00
    1,206.59
    2,413.18
    3,619.77
    1,348.07
    2,696.14
    4,044.21
    161,421.00
    322,842.00
    484,263.00
    113,287.20
    226,574.40
    339,861.60
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report